SNAPSHOTS —Alan Franciscus, Editor-in-Chief
Article: Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies—J. Grebely, et. al.
SOURCE: Open Forum Infectious Diseases, Volume 5, Issue 2, 1 February 2018, ofy001, https://doi.org/10.1093/ofid/ofy001
Study Aims and Results: This study analyzed phase 3 treatment data of sofosbuvir-containing therapies to understand the outcomes among people who received opioid substitution therapy (OST) compared to people who did not receive OST. The study included HCV genotypes 1 through 6. There was a total of 4,743 people in the phase 3 studies of sofosbuvir-based therapies (interferon-free) who received OST—194 (4%) received either methadone (113 patients), buprenorphine (75 pts) or neither (6 pts). The OST patients were somewhat younger, and more likely to be male, treatment naïve, genotype 3, and cirrhotic. The treatment period was 8 to 24 weeks.
The analysis revealed that there were no or very little differences in the groups who received OST and those who did not: treatment completion rates (97% vs 99%), cure rates (94% vs 97%), relapse rate (0.5% vs 2.1%), side effects (78% vs 77%), or serious side effects (3.6% vs 2.4%). Additionally, the cure rates were similar for those with cirrhosis (99% vs 95%) and HCV genotype 3 (95% vs 95%).
Conclusions: Treatment with sofosbuvir-based therapies is safe and effective in people with HCV taking OST.
Editorial Comments: The current analysis provides additional evidence that people who receive OST can be successfully treated with DAA-based therapies.
Share This Page